Tvardi Therapeutics, Inc. (TVRD) stock
TVRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.18+0.02 (+2.16%)
Close on Nov 13, 2026Market cap $15.74MP/E –Yield 0.00%
Tvardi Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Tvardi Therapeutics's ebitda for the twelve months ending Sep 30, 2026 was -$27.50M. For fiscal 2025 it was -$26.65M. The highest annual figure on record is $5.59M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$26.65M | – |
| FY2024 | Dec 31, 2024 | -$28.01M | – |
| FY2023 | Dec 31, 2023 | -$121.24M | – |
| FY2022 | Dec 31, 2022 | -$87.29M | – |
| FY2021 | Dec 31, 2021 | -$88.84M | -1688.0% |
| FY2020 | Dec 31, 2020 | $5.59M | – |
| FY2019 | Dec 31, 2019 | -$111.48M | – |
| FY2018 | Dec 31, 2018 | -$77.01M | – |
| FY2017 | Dec 31, 2017 | -$58.99M | – |
| FY2016 | Dec 31, 2016 | -$56.94M | – |
| FY2015 | Dec 31, 2015 | -$24.35M | – |
| FY2014 | Dec 31, 2014 | -$17.29M | -3232.1% |
| FY2013 | Dec 31, 2013 | $552.00K | – |
| FY2012 | Dec 31, 2012 | -$5.22M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$6.30M | – |
| Q2 FY2026 | Jun 30, 2026 | -$6.61M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.03M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.56M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.91M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.85M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.33M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.78M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.65M | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.18M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.62M | – |
| Q4 FY2023 | Dec 31, 2023 | -$32.53M | – |
| Q3 FY2023 | Sep 30, 2023 | -$28.84M | – |
| Q2 FY2023 | Jun 30, 2023 | -$32.28M | – |
| Q1 FY2023 | Mar 31, 2023 | -$27.59M | – |
| Q4 FY2022 | Dec 31, 2022 | -$31.25M | – |
| Q3 FY2022 | Sep 30, 2022 | -$23.78M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.41M | – |
| Q1 FY2022 | Mar 31, 2022 | -$27.85M | – |
| Q4 FY2021 | Dec 31, 2021 | -$33.46M | -142.7% |
| Q3 FY2021 | Sep 30, 2021 | -$1.06M | – |
| Q2 FY2021 | Jun 30, 2021 | -$30.82M | – |
| Q1 FY2021 | Mar 31, 2021 | -$23.50M | – |
| Q4 FY2020 | Dec 31, 2020 | $78.35M | – |
| Q3 FY2020 | Sep 30, 2020 | -$16.97M | – |
| Q2 FY2020 | Jun 30, 2020 | -$25.84M | – |
| Q1 FY2020 | Mar 31, 2020 | -$29.95M | – |
| Q4 FY2019 | Dec 31, 2019 | -$29.92M | – |
| Q3 FY2019 | Sep 30, 2019 | -$34.38M | – |
| Q2 FY2019 | Jun 30, 2019 | -$24.09M | – |
| Q1 FY2019 | Mar 31, 2019 | -$23.08M | – |
| Q4 FY2018 | Dec 31, 2018 | -$21.93M | – |
| Q3 FY2018 | Sep 30, 2018 | -$20.39M | – |
| Q2 FY2018 | Jun 30, 2018 | -$17.70M | – |
| Q1 FY2018 | Mar 31, 2018 | -$17.00M | – |
| Q4 FY2017 | Dec 31, 2017 | -$14.45M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.83M | – |
| Q2 FY2017 | Jun 30, 2017 | -$9.51M | – |
| Q1 FY2017 | Mar 31, 2017 | -$22.20M | – |
| Q4 FY2016 | Dec 31, 2016 | -$22.20M | – |
See a number that looks wrong?